{
    "medicine_id": "6aaeba9c18c8b561e8dec8f62c106e567cdc7710",
    "platform_id": "DB04996",
    "metadata": {
        "name": "Potiga 50 mg 1 Tablet film coated",
        "composition": "50 mg 1 Satraplatin",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in lung cancer prostate cancer and solid tumors",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "NA",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00012",
                        "description": "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Satraplatin"
                    },
                    {
                        "drugbank-id": "DB00016",
                        "description": "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Satraplatin"
                    },
                    {
                        "drugbank-id": "DB08894",
                        "description": "The risk or severity of Thrombosis can be increased when Peginesatide is combined with Satraplatin"
                    },
                    {
                        "drugbank-id": "DB09107",
                        "description": "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol epoetin beta is combined with Satraplatin"
                    },
                    {
                        "drugbank-id": "DB01030",
                        "description": "The risk or severity of adverse effects can be increased when Satraplatin is combined with Topotecan"
                    },
                    {
                        "drugbank-id": "DB00252",
                        "description": "Satraplatin can cause a decrease in the absorption of Phenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB01320",
                        "description": "Satraplatin can cause a decrease in the absorption of Fosphenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy"
                    },
                    {
                        "drugbank-id": "DB01229",
                        "description": "The risk or severity of adverse effects can be increased when Satraplatin is combined with Paclitaxel"
                    },
                    {
                        "drugbank-id": "DB01248",
                        "description": "The risk or severity of adverse effects can be increased when Satraplatin is combined with Docetaxel"
                    },
                    {
                        "drugbank-id": "DB06772",
                        "description": "The risk or severity of adverse effects can be increased when Satraplatin is combined with Cabazitaxel"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}